Comparative Study Shows Striant(R) Consistently Achieves Normal Testosterone Levels Researchers Conclude Latest FDA-Approved Hypogonadism Therapy is a Valuable Treatment Option for Testosterone-Deficient Men LIVINGSTON, N.J., May 4 /PRNewswire-FirstCall/ -- Results of an international multicenter study comparing the steady-state pharmacokinetics and tolerability of Striant(R) (testosterone buccal system) (CIII) with a testosterone containing skin patch show that use of Striant produces physiologic (normal) testosterone levels in hypogonadal men and achieves testosterone concentrations within the normal range. Hypogonadism, a condition associated with a deficiency or absence of endogenous testosterone, affects nearly five million American men. Study results are published in this month's issue of the Journal of Clinical Endocrinology and Metabolism. In the open-label, parallel arm study, 66 patients with a morning serum testosterone less than 6.94 nmol/liter were randomized into two groups. Of the 57 patients who completed the study protocol, 29 patients were treated with Striant (30 mg) twice daily for seven days, while 28 patients in the other group applied a transdermal testosterone patch daily for seven days. Serum testosterone and dihydrotestosterone (DHT) concentrations were measured periodically over six days and then serially over the last 24 hours of the study. The average serum testosterone concentration over 24 hours showed a mean of 18.74 nmol/liter in the Striant group, and 12.15 nmol/liter in the transdermal patch group (P